• Clinical endpoints attained in phase III clinical trials of LuMeBlue for adenoma detection during colonoscopy
  • Establishment of Aries Pharmaceuticals Ltd, Dublin and its subsidiary Aries Pharmaceuticals Inc, San Diego to market and distribute Eleview, LuMeblue, Zemcolo and Remimazolam in the USA
  • Licensing in of Remimazulam for the US territory.
  • Investment of EUR 9.6 million for 9% of Paion AG, listed on Frankfurt Stock Exchange
  • Approval of Eleview™ in EU
  • Clinical endpoints attained in second pivotal phase III trial for Rifamycin SV MMX
  • Cosmo Pharmaceuticals NV becomes a Dutch Company


  • Licensing agreement with Ferring for Cortiment in Japan.
  • Spin-off of Cassiopea SpA on SIX
  • Cosmo Pharmaceuticals becomes a Luxembourg company


  • Shareholders approve change of seat to Luxembourg
  • Cosmo announces excellent results in phase II for CB-03-01 acne
  • Cosmo announces new product SIC 8000 (sub mucosal injectable composition) addressing unmet need in polyp removal
  • Cosmo announces sale of last part of Santarus shares


  • Cosmo announces launch of Uceris® in the US
  • Cosmo announces approval of Cortiment® in the Netherlands.


  • Cosmo announces acceptance of NDA filing by FDA for Uceris®in February.


  • Cosmo announces filing of NDA for Uceris®(Budesonide MMX) in the USA in December.
  • Cosmo announces the additional approval of LIALDA in the U.S. for the maintenance of remission in patients with ulcerative colitis.
  • Cosmo announces filing of MAA for Cortiment®(Budesonide MMX) in the EU in May.
  • Cosmo announces very positive results of the first parts of the phase II clinical trials following the live transmission of Blu-Colonoscopy at the International Meeting for Advanced Gastroenterology Endoscopy at Humanitas Hospital in Milano.


  • Cosmo announces successful results of phase III trials for Budesonide MMX®in the EU and in the US.
  • Cosmo announces delisting of BioXell.
  • Cosmo announces final results of its tender offer for BioXell.


  • Cosmo's CB-03-01 phase II pilot study in acne demonstrates superiority over Retin A®on 11 December.
  • Cosmo publishes the public tender offer to acquire BioXell on 8 December.


  • Strategic collaboration with Santarus for U.S rights to Budesonide MMX®and Rifamycin MMX®on 15 December.
  • Licensing agreement with Dr. Falk for Rifamycin SV MMX®.
  • Cosmo awarded US patent for use of its MMX®technology.


  • UK Market launch of Mezavant XL®by Shire plc on 05 November.
  • Licensing agreement with Ferring for Budesonide MMX®.
  • US Market launch of Lialda®by Shire plc on 19 March.
  • IPO on the Swiss Stock Exchange (SWX) on 12 March.


  • FDA approval for the manufacturing of tablets to the USA.
  • Completion of 2.000 sq m plant in Lainate, Milan.


  • Completion of first financing round of €20.4 million by Cosmo Holding S.p.A.
  • Lialda®/Mezavant®Supply Agreement with Shire plc.


  • Opening of an R&D laboratory in Catania, Italy.


  • Lialda®/Mezavant®globally out-licensed to Giuliani S.p.A./ Shire plc.


  • Filing of the first MMX®Multi Matrix technology patent for the controlled release of tablets in the gastro-intestinal tract.


  • Strategic decision to develop novel oral formulations of off-patent pharmaceutical products to generate new patentable applications.


  • Foundation of Cosmo S.p.A. by purchasing contract manufacturing unit in Lainate (Milan) from Parke Davis (now Pfizer Group).
Delivered by Investis – link to website (opens in a new window)